Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal palivizumab for RSV prevention
NL-OMON55390Phase 2Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of palivizumab in respiratory syncytial virus disease (RSV) (4 arms), sponsored by University Medical Center Utrecht. Primary endpoints: Self-reported local and systemic symptoms, Serious adverse events and 1 more. Started Oct 2018; status: active, not recruiting.
02
Drugs
palivizumab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on NL-OMON55390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55390.